# The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?

Yann Fichou, Youssra K Al-Hilaly, François Devred, Caroline Smet-Nocca, Philipp O Tsvetkov, Joke Verelst, Joris Winderickx, Nick Geukens, Eugeen Vanmechelen, Audrey Perrotin, et al.

<figure><img src="image_1.png" /></figure>

## To cite this version:

Yann Fichou, Youssra K Al-Hilaly, François Devred, Caroline Smet-Nocca, Philipp O Tsvetkov, et al.. The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?. Acta Neuropathologica Communications, 2019, 7 (1), 10.1186/s40478-019-0682-x. hal-02055894

HAL Id: hal-02055894

https://amu.hal.science/hal-02055894

Submitted on 4 Mar 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>
REVIEW

Open Access

<figure><img src="image_3.png" /></figure>

Check for
updates

# The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?

Yann Fichou¹, Youssra K. Al-Hilaly²,³, François Devred⁴, Caroline Smet-Nocca<fnref n="5" />, Philipp O. Tsvetkov⁴, Joke Verelst⁶, Joris Winderickx⁶, Nick Geukens⁷, Eugeen Vanmechelen⁸,⁹, Audrey Perrotin⁹, Louise Serpell², Bernard J Hanseeuw¹⁰,¹¹, Miguel Medina¹²,¹³, Luc Buée<fnref n="14" />*† and Isabelle Landrieu<fnref n="5" />*†

**Abstract**

Insights into tau molecular structures have advanced significantly in recent years. This field has been the subject of recent breakthroughs, including the first cryo-electron microscopy structures of tau filaments from Alzheimer's and Pick's disease inclusions, as well as the structure of the repeat regions of tau bound to microtubules. Tau structure covers various species as the tau protein itself takes many forms. We will here address a range of studies that help to define the many facets of tau protein structures and how they translate into pathogenic forms. New results shed light on previous data that need now to be revisited in order to up-date our knowledge of tau molecular structure. Finally, we explore how these data can contribute to the important medical aspects of this research - diagnosis and therapeutics.

**Keywords:** Tauopathies, Alzheimer's disease; tau structure; tau aggregation, Alzheimer's disease diagnosis, Amyloid

**Introduction**

The investigation of tau molecular structure covers its primary sequence, local elements of secondary structure and global fold and, finally, complex formation and aggregation. Tau is defined as an intrinsically disordered protein (IDP) and is present as six isoforms in human brain (ranging from 352 to 441 amino acid residues, Fig. 1), resulting from alternative splicing [53, 63]. All these isoforms are themselves subjected to multiple post-translational modifications (PTMs), the best studied being phosphorylation. Its PTMs are incredibly complex because they are numerous and can combine in many ways [105] and these are also prone to cross-talk [20, 85, 86]. To make matters even more complex, tau proteins are subjected to proteolytic degradation [33, 171]. Ratios of isoforms [37], level of phosphorylation and proteolytic degradation all contribute to normal and pathological tau activity. Tau has many binding partners, and is most notoriously bound to microtubules (MTs) [49, 73, 76, 93, 150, 162, 167], but also to

many regulatory proteins [90, 115], DNA [17, 122] or membrane [2]. The later non-standard functions of tau were previously reviewed following EuroTau 2017 gathering [141].

Tau is associated with several neurodegenerative diseases, termed tauopathies, in which it is found as insoluble deposits associated with other cellular components [13]. Tau is the principal component of paired helical filaments (PHFs) and straight filaments (SFs) [23, 54], which form the intraneuronal fibrillar deposits known as neurofibrillary tangles (NFT) in Alzheimer's disease (AD) and leading ultimately to neurofibrillary degeneration. The tau filaments have cross-β structure and therefore share the common characteristics of amyloid [18]. The aggregates themselves are not a single homogenous family. In addition to mature insoluble aggregates, which have different disease-specific structures, tau is found as oligomeric forms, loosely defined, but thought to have a very toxic effect [42, 62]. Thus, inhibition and/or clearance of oligomeric hyperphosphorylated tau could be a more effective therapeutic target than the fibrilized protein [82, 143]. Because tau filaments were thought to be composed of the microtubule binding region (MTBR, Fig. 1), it has been common practice to use tau fragments containing only this region, either in its 3R (isoform containing 3 repeat domains) version

<figure><img src="image_4.png" /></figure>

BMC

© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

<footnote>* Correspondence: luc.buee@inserm.fr; Isabelle.landrieu@univ-lille.fr
Luc Buée and Isabelle Landrieu are co-senior authors.</footnote>

<footnote n="14">¹⁴University of Lille, Inserm, CHU-Lille, UMRS1172, 59000 Lille, France</footnote>

<footnote n="5">⁵University of Lille, CNRS, UMR8576, 59000 Lille, France
Full list of author information is available at the end of the article</footnote>
<figure><img src="image_5.png" /></figure>

(K19) or 4R (isoform containing 4 repeat domains) version (K18), as model peptides for aggregation studies. Two homologous hexapeptides named PHF6* (275VQIINK280) and PHF6 (306VQIVYK311) located at the start of the second and third repeat regions (R2 and R3) (Fig. 1) of tau MTBR, respectively, are essential for tau aggregation [157]. PHF6* is thought to be the stronger driver of aggregation [135]. PHF6(*) (PHF6* and PHF6) peptides spontaneously aggregate in solution in contrast to the full-length tau which is a highly soluble protein. The atomic structures of the two hexapeptides reveal the capacity of these segments to form interdigitated steric-zipper interfaces that seed tau aggregation [79, 131, 135].

To grasp the molecular characteristics of tau structures is challenging. First of all, as a large IDP, tau is flexible and dynamic and requires high-field nuclear magnetic resonance spectroscopy (NMR) to collect molecular detail. Tau has a low complexity amino-acid sequence, and recently joined the club of proteins with the capacity to form liquid droplets [8]. More than an oddity, it seems that this form of tau is able to seed MTs assembly in a highly efficient manner and might have consequences for aggregation initiation [8, 161]. Aggregates are solid and heterogeneous, and therefore are challenging to characterize by classical structural techniques. Finally, the molecular details of tau interaction with MTs are difficult to define due to the dynamic nature of the complex, the MTs being by themselves in dynamic equilibrium. Progress in understanding the mechanistic role of tau as a microtubule associated protein came from cryo-electron microscopy (cryo-EM), which offered a view of tau repeats bound to MTs [76]. Recent breakthroughs, detailed in this review, came from progress in sophisticated biophysical techniques brought together with immense efforts and ingenuity.

We here will focus on tau molecular structures, highlighting the techniques required for its characterization, and summarizing the results that may provide basis for a better

definition of tau pathological forms and the pathway(s) of pathogenesis. Finally, we conclude by showing how these results can translate into better targeted tau-antibodies for diagnostic and into progress in tau imaging. This review does not intend to be a full-coverage of the literature but rather to reflect the lively discussion that took place on the EuroTau meeting 2018, in Lille, France.

## Aggregate structure: From heparin-induced structure to native conformation

The characterization of amyloid structures is challenging because they are only partially ordered and often heterogeneous. Crystallization has been possible for short peptides [125, 135], but not for full-length proteins. Because of this lack of precise structural information, the relationship between amyloid structure and pathology remains a heated debate for many proteins; tau is no exception.

The large majority of structural studies in the last few decades have been carried out on aggregates made out of recombinant tau constructs. Limited proteolysis applied on K18, K19 and the full-length tau2N4R showed that the amyloid core is formed by the second half of R1, R2 (when present), R3 and the first half of R4 [156]. Solid-state NMR (ssNMR) confirmed that, in K19, β-sheets are formed in the end of R1, in the full R3 and the beginning of R4 [12]. Another ssNMR study showed more precisely that only 19 residues, 306–324, formed β-sheets while the rest remains relatively dynamic [29], in agreement with proton/deuterium exchange experiments. They also showed that the packing is in-register and parallel, confirming what was observed earlier by electron paramagnetic resonance (EPR) spectroscopy [91]. Furthermore, Bibow and co-workers [19] showed that the N- and C-termini (0–212, 399–441) are highly mobile while the central region is too immobile to be detected by solution NMR. They also show electrostatically-driven long-range interactions between the filament core and both C- and N-terminal extremity.
While recombinant filaments have shed light on many aspects of tau aggregation mechanisms and structure, it is important to note that their formation presents potential biases: (i) the use of an arbitrary cofactor, (ii) the absence of PTMs, (iii) the use of an arbitrary tau segment. Therefore, it remains today unclear how much of the atomic arrangements found in recombinant filaments is biologically relevant.

When extracting aggregates from brain, trypsin resistant cores show different pattern in gel electrophoresis for Pick's disease (PiD), AD, progressive supranuclear palsy (PSP) and corticobasal degeneration, suggesting different core composition/structure for each disease [148].

The recent technological breakthroughs of cryo-EM have allowed to solve two structures of tau aggregates, extracted from AD- and PiD-affected human brains [40, 44]. These structures represent major advancements in the field as they provide the first high-resolution molecular architectures of the tau filament cores extracted from human tissues. The AD protofilament core is similar for PHFs and SFs and is composed of R3 and R4 repeat domains as well as 10 residues in the C terminus region (306–378), and exhibit a Greek-key conformation [44], reminiscent of the α-synuclein fibril structure [152]. The core also forms a region of β-helix similar to the conformation identified in the prion-forming domain of HET-s, in which it plays a crucial role for infectious properties [159]. The major difference between SFs and PHFs lies in the interaction between the two protofilaments. It should be noted that additional electron densities were detected in the region before R3, strongly suggesting that part of R2 (for 4R tau) or R1 (for 3R tau) is also partially structured in AD filaments. Similar structural features were found in several sporadic and inherited AD brains, suggesting that this structure is a hallmark of AD [41]. The PiD filament core encompasses AD's (306–378) and also includes half of the R1 repeat [40]. The structure shows that the arrangement of the R1 (254–274) segment is not compatible with the equivalent sequence in R2 (285–305), providing an explanation as to why PiD aggregates contain only 3R tau isoform. Although most of the β-sheets in the region 306–354 locally align between AD and PiD, the filament core from the latter possesses neither a Greek-key shape nor a β-helix, characteristic of AD filaments. It should be noted that although cryo-EM provided two well-defined structures, it does not exclude the existence of other minor aggregate species, which would be excluded during the image analysis process.

The high-resolution structures of brain-extracted tau aggregates reveal that filaments formed by recombinant full-length tau seem to be different from in-vivo filaments. Indeed, ssNMR and limited proteolysis predicted immobile and/or protected regions (see paragraphs above) different from either AD or PiD filament core. It

was notably unexpected to have a structured core extending beyond the R4 region. This finding suggests that the widely used K19 and K18 fragments, composed exactly of the 3 or 4 repeat domains, might not be able to model PiD and AD filament cores as they lack the C-terminal region 368–378. In addition, it was shown by EPR spectroscopy that heparin-induced filaments from a tau fragment 255–441 do not reproduce the large domain folds present in AD and PiD cores [43]. The authors also demonstrated that heparin filaments are highly heterogeneous. These differences between brain-extracted aggregates and heparin-induced filaments were later confirmed and further described by cryoEM [170].

The difficulty in obtaining biologically relevant structures with recombinant proteins could in principle be overcome by seeding aggregation using tissue-extracted material. Seeding refers to the process by which monomers are recruited by premade aggregate, therefore multiplying the quantity of aggregate, either in vitro or in vivo. Although it is generally thought that seeding faithfully propagates the structure of the seed, this assumption has not yet clearly been demonstrated at high resolution. On the one hand, cellular seeding assays have showed that the macroscopic aspects as well as the patterns of limited proteolysis of a given strain can be maintained through several seeding generations [75], suggesting the propagation of the seed structure. On the other hand, different tau constructs (tau2N4R, K18 and K19) have been shown to form different limited-proteolysis signature, which cannot be propagated for more than one generation of in-vitro seeding [111]. The authors suggested that the seeded protein, and not the seed, determine the pattern of the final filament. EPR spectroscopy has been used to characterize the population of aggregates at high resolution by measuring intramolecular distance distributions inside the filament core. Meyer and coworkers showed that filaments species are selected through seeding cycles depending on their mechanical properties and the environmental conditions [100]. The same group highlighted a cross-seeding barrier between different fragments (in particular K18 cannot seed K19 while K19 can seed K18) that they attributed to conformational incompatibility between the seed and the seeded species [138]. They furthermore showed that the seeded barrier can be modulated by single-point mutations in the core domain or by interactions with the N-and C-terminal tails [100, 163]. It should be noted that in-vitro seeding is often assisted by a cofactor (RNA or heparin), which was recently shown to be an essential component of the filaments as they are necessary to ensure stability of either seeded or non-seeded filaments [43]. The biological relevance of these co-factors is not well established, as there are many potential co-factor candidates in the cellular environment. Heparan-sulphate proteoglycans were reported to be associated with AD tau filaments [51],
although they are not present in the intracellular medium where tau is mostly found. RNA was also shown to be sequestered in tau fibers from several tauopathies [50]. Other proteins might also be potent co-factors such as α-synuclein [106] and even nuclear pore proteins [38].

## Tau fragments and aggregation

Tau truncation plays an important role in AD pathology [113]. Truncated tau proteins were initially identified as constituents of the pronase-resistant PHF core [165, 166], and it has been suggested that tau truncation drives the pathological conversion of wild-type tau at neuritic plaques [83]. Caspase activation associated with tau truncation led to tau aggregation in tau transgenic mice and expression of a tau fragment cleaved at Asp421 (mimicking caspase truncation) into wild-type mice led to the appearance of intracellular aggregates [32]. Intriguingly, gingipain proteases secreted by *Porphyromonas gingivalis*, a pathogen involved in chronic periodontitis and able to invade the brain, have been proposed to affect tau by direct gingipain proteolysis as well as gingipain activation of human proteases that act on tau [36].

In vitro, C-terminal truncated tau at Glu391 or at Asp421 have a higher propensity to aggregate than full-length tau when using an aggregation inducer [1, 45, 168]. A truncated form of tau has been identified in AD brain tissue which extends from residue 297 to residue 391, known as dGAE [70, 166]. The antibody mAb423 can be used to identify the specific fragments which terminate at Glu391 [60], and has been shown to bind to intra- and extracellular NFTs in AD brain tissue [98, 112, 139]. The presence of this truncated tau form was confirmed using MS analysis for pronase-un-treated PHFs extracted from AD brain (Braak stage V: [21]). This resolved the long running debate as to whether tau truncation is a result of pronase treatment, or whether it occurs naturally in disease [173].

Polyanions such as heparin have been widely used to produce tau aggregates for in vitro studies [15, 18, 51, 157]. However, recent work using circular dichroïsm (CD) revealed that heparin interacts directly with a drug that was produced by TauRx Therapeutics called leuco-methylthioninium [3], thus developing a new heparin-free in vitro model became essential. In addition, heparin-induced filaments (see above) were found structurally different from those in AD brain [43].

A new in vitro model system was developed to produce aggregates from the truncated PHF-core tau fragment, dGAE, using physiological conditions and without any additives [3, 4]. The resulting filaments closely resembled PHFs found in AD brain (Fig. 2), sharing a similar periodicity of 65–80 nm [4, 142]. Furthermore, the preparation produces a subset (about 10%) of SF-like filaments, similar to the ratio found from tissue extraction [44]. dGAE includes the PHF core region identified

in the recently reported PHF structure [41, 44]: residues 323–335 of R3 and 354–369 of R4. Thus, this in vitro model will help researchers in the field to better understand the tau misfolding process into PHFs and SFs and the molecular mechanism of tau propagation.

The role of disulphide links in tau assembly into PHF remains still unclear in full-length tau and in various truncated tau fragments [66]. Full length tau in COS cells (fibroblasts from monkey kidney tissue) has been reported to form two types of dimer, one cysteine-dependent and the other, cysteine-independent [129]. Similarly, dGAE is able to form both dimer types [4]. Variants of full-length tau (C291A/C322A) and truncated tau dGAE (C322A) have been shown to be able to form filaments [4, 129]. Importantly, the self-assembly and elongation of the filaments formed by dGAE is enhanced under reducing conditions, signifying that the cysteine found at position 322 is not required to form a disulphide bond for assembly of this truncated region [4]. This is backed by the structural details of AD isolated PHF which show Cys322 to be buried in the interior of the structure [44], in contrast with the PiD fold where it is exposed to solvent [40]. This suggests that disulphide bond formation is not favourable to form AD PHF. In addition, inhibition of tau aggregation using a small molecule, leuco-methylthioninium, was found to be cysteine-independent [3], confirming that disulphide bond formation is not necessary for tau assembly.

## Tau phosphorylation and aggregation

Tau phosphorylation is physiological and regulates, among many interactions, the tubulin polymerization capacity of tau, to maintain the dynamic character of MTs in normal

<figure><img src="image_6.png" /><figcaption>**Fig. 2** Negative stain EM image of in vitro PHFs produced from dGAE in additive-free conditions at pH 7.4 and 37 °C [4]</figcaption></figure>
physiological conditions, while tau protein found in PHF
is hyperphosphorylated [55]. In pathological conditions,
the aggregation of tau is commonly described as being a
consequence of tau hyperphosphorylation [5, 158]. The ini-
tial characterization was performed by mass spectrometry
(MS) on PHFs isolated from patients and showed an aver-
age of 20 modified phosphorylation sites compared to an
estimated four to five for the soluble protein [56, 62, 103].
In addition, in vitro tau aggregation assays performed by
addition of polyanionic molecules, such as heparin, is
proposed to mimic the seeding effect of phosphorylated tau
on the unphosphorylated protein [6]. Finally, phosphory-
lated tau, extracted from brain of AD affected patients, or
in vitro phosphorylated by rat brain extract, was shown to
be more sensitive to aggregation in in vitro assays, com-
pared to the unmodified wild-type protein [5]. From these
early results, an attractive model of the impact of phospho-
rylation on tau pathogenesis was proposed: hyperpho-
s phosphorylated tau would detach from the MTs and aggregate,
phosphorylation initiating both aspects.

Although quite seductive, this model does not recapitu-
late all recent results, and although it has its merits, it is
probably still a simplified view of the impact of tau phos-
phorylation on its aggregation propensity. Indeed, hyper-
phosphorylated tau, obtained by in vitro phosphorylation
with recombinant ERK kinase (15 phosphorylated sites),
rat brain extract (18 phosphorylated sites) [123] or
obtained from recombinant expression in insect cells (10
or 20 phosphorylation sites) is not significantly more sus-
ceptible to in vitro aggregation than its wild-type counter-
part [149]. In the case of ERK-phosphorylated tau, a few
filaments are observed by EM from the pellet of the aggre-
gation assay. However, the aggregation is not detected by
the classical Thioflavin T fluorescence (ThT) associated
with β-sheet aggregate formation in in vitro assay, indica-
ting that the filaments are a minor fraction of tau in the
sample [123]. Accordingly, tau which was highly phos-
phorylated by recombinant expression in insect cells
shows increased oligomerization but not tau fibrillization
per se [149]. The observation that in vitro aggregation
propensity of the in vitro hyperphosphorylated tau is low
does not exclude that it could be a trigger in a cellular
context. Indeed, in cellular context additional elements
are in play [42] some depending on Tau phosphorylation
status, such as interaction with co-factors [50, 51],
increase in local concentration due to detachment from
the MTs [7] and/or deficient degradation [126], as well as
Tau proteolysis (see preceding paragraph).

In addition, not only the number of phosphorylation
sites, but also phosphorylation positions should be consi-
dered, as not all phosphorylations are equivalent. Most
likely a specific combination of phosphorylation sites lies
at the basis of tau becoming oligomerisation/aggregation
prone [154], although the exact combination is unknown.

Keeping this point in mind, a decrease phosphorylation of
tau, globally or at some sites, is compatible with an in-
crease aggregation, depending on which sites are affected.

Moreover, tau is described to misfold on its pathway
of aggregation, although the definition of what is a mis-
folded IDP is not straightforward. Some data indicate
early conformational changes that could be early stages
of misfolding taking place. For example, the MC-1 or
Alz50 antibodies [24] recognize conformational epitopes
and detect abnormal tau in early stages of AD. Pseudo-
phosphorylations (replacement of Ser and Thr residues
by Glu residues) to reproduce the AT8 (the AT8 epitope
is defined in this study as a combination of pSer199,
pSer202 and pThr205), AT100 (pThr212 and pSer214),
and PHF1 (pSer396 and pSer404) epitopes were used to
evaluate the impact of the phosphorylation on tau global
conformation based on distance measurements from
FRET-pairs. A more compact global fold was found com-
pared to the wild-type, increasing contact between the N
and C-terminal regions (paper-clip fold), better reproduc-
ing the conformation recognized by the conformational
antibody MC-1 that targets AD-tau [71]. A recent study
based on cross-linking coupled to MS probed the structural
differences between seed-competent or inert tau monomers,
including tau monomers purified from AD and control
brains. In these seed-competent monomers, the amyloido-
genic peptides PHF6(*) were more accessible compared to
inert (unable to seed aggregation) purified tau monomers
from control brain [101]. Shielding the PHF6(*) sequences
in the inert monomer was attributed to a preferential hair-
pin conformation of tau around these regions. This study
was in agreement with earlier work based on EPR spec-
troscopy showing that exposure of tau to aggregation-pro-
moting cofactor heparin opens up and exposes PHF6(*)
regions [39]. These studies suggest a structural origin for
the initiation of tau aggregation with conversion of tau
monomer from an inert to an aggregation-prone form that
could be viewed as an early misfolding intermediate.

In view of these data, and at the molecular level, two
points should be considered to refine the concept of the
impact of tau phosphorylation on its susceptibility to
aggregation: 1/ the effect of specific pattern of phosphory-
lation and 2/ the impact of these phosphorylation events,
not only on the electrostatic character of tau, but also on
tau local structure and global fold.

With these points in mind, the impact of phosphoryl-
ation on Ser202 and Thr205 was investigated using NMR
spectroscopy. pSer202 and pThr205 are part of the epitope
for the well-known AT8 monoclonal antibody used in
many studies to detect what is defined as a pathological tau
protein. What was observed for the AT8-phosphorylated
tau is the formation of a particular dynamic turn conform-
ation, which is stabilized by a hydrogen bond from the
phosphate of the pThr205 residue side-chain to the amide
proton of Gly207. The turn conformation is further stabilized by Arg209 and Arg211 residues that face the pSer202/pThr205 residues with Gly207 located in the middle of the positively and negatively charged sequences, inducing backbone flexibility [46]. Tau protein showing this pattern of phosphorylation, in combination with absence of phosphorylation of the Ser262 residue to avoid interference, is not more sensitive to aggregation than the wild-type protein [35]. However, combined phosphorylation at the Ser202/Thr205/Ser208 sites, together with absence of phosphorylation of the Ser262 residue, yields a tau sample that forms filaments, as observed by ThT fluorescence and EM, and this triple phosphorylation state of AT8 epitope alone is sufficient to induce aggregation of tau in vitro [35]. This triple phosphorylation pattern was suggested to represent a better epitope for the AT8 monoclonal than the double Ser202/Thr205 phosphorylation [89]. The crystal structure of the complex of antibody with a pSer202/pThr205/pSer208 phosphorylated tau peptide showed no turn conformation of the bound epitope. Accordingly, in solution, no turn-like conformation was detected for the triple-phosphorylated AT8 epitope. Whether the conformation could be part of the increased susceptibility to aggregation was investigated using a mutated tau protein with Gly207 replaced by a Val residue exhibiting a bulky, Cβ-branched side chain. This mutation disrupts the formation of the dynamic turn, even in the presence of pSer202/pThr205. Interestingly, susceptibility to in vitro aggregation of a tau fragment containing the Gly207Val mutation is increased compared to the pSer202/pThr205 or unphosphorylated tau protein. These experiments show that a conformational change induced, either by a mutation (although Gly207Val mutation has never been found in any tauopathy) or a specific phosphorylation pattern, could alter the aggregation propensity of tau, and a large number of phosphorylated sites is not required to change this propensity. It might be that not only the additional charges, but also the subtle impact on tau dynamic structure is an important parameter. The molecular mechanism by which a dynamic turn located at the AT8 epitope could prevent in vitro tau aggregation (in the absence of heparin inducer) remains to be defined. It might also not be the only pattern of phosphorylation that could have this protective effect. To reconcile these in vitro data with the body of research conducted in the cellular context is not straightforward. First, the AT8 can recognize both the double pSer202/pThr205 and triple pSer202/pThr205/pSer208 phosphorylation pattern that showed differential effect on tau aggregation. Secondly, AT8 positive tau species are modulated by other phosphorylation, and, for example, phosphorylation of Ser262 prevents in vitro aggregation [133], whatever the status of the AT8 epitope (2 or 3 phosphorylations).

Nevertheless, the structural studies show a facet of the complex impact of tau phosphorylation on

aggregation. Although tau is disordered, it can indeed be described as misfolded at the global and local level, due to specific phosphorylation.

## Zinc binding and tau aggregation

Zinc, the most abundant trace metal in brain, is known to play an important regulatory role both in a number of physiological processes, including neuronal growth and signal transduction, and in the pathogenesis of several neurodegenerative diseases such as AD [104, 160].

In physiological processes, zinc ions are usually involved in maintaining structure and function of hundreds of proteins, including enzymes of all known classes, transcription factors, receptors, and signalling proteins. It has even been reported that zinc was able to induce some level of structure formation in intrinsically disordered tau protein (Fig. 3). Indeed, CD spectra of tau0N4R isoform showed that zinc acts as a strong promoter of protein conformational changes [65]. Further analysis of these CD spectra using CAPTO tool [164] revealed significant increase in β-sheet content upon zinc binding, from 1% in the absence of zinc ions to 5 and 18% in the presence of 0.25 µM and 0.5 µM, respectively. This is also in-line with dynamic light scattering data presented at EuroTau meeting 2018 obtained on tau2N4R, which demonstrate a reduction in tau hydrodynamic radius in solution upon zinc binding, from 12.2 to 8.8 nm [127]. Such tau compaction and gain of structure may be explained by location of amino acids implicated in zinc chelation. Indeed, zinc ions are chelated by Cys291, Cys322 and probably by His330, His362 as shown using tau (244–372) fragment and its mutants [102]. Chelation by these residues, located in R2-R3 repeats, pulls together distant regions of tau and induces its altered conformation (Fig. 3). This was confirmed by performing Isothermal Titration Calorimetry (ITC) to monitor zinc binding to tau fragments with mutated cysteine and histidine residues. The experiments revealed a stoichiometry close to 0.5, indicative of tau fragment dimerization and of the absence of intramolecular chelation of zinc. Another study based on ITC measurements on Zn binding to tau2N4R or its cysteine mutants [64] suggested additional zinc binding sites. ITC analysis of tau2N4R interaction with zinc, presented at Eurotau 2018, confirmed the existence of one high ($N = 1.0 \pm 0.1$; $Ka = 2.0 \pm 0.5 \times 10^6 M^{-1}$) and of three low affinity binding sites ($N = 3.2 \pm 0.3$; $Ka = 5.9 \pm 1.7 \times 10^4 M^{-1}$) [127]. The high affinity site most probably corresponds to the one described previously [102] in tau (244–372) fragment, formed by two cysteines and two histidines from R2 and R3 domains (Fig. 3). Since the three auxiliary sites were not detected in tau (244–372) fragment, they could be located in N- and/or C- terminal regions, which have many potential zinc chelating amino acids. Even if we now have evidence regarding the specific tau regions implicated
<figure><img src="image_7.png" /></figure>

in zinc binding, the impact of zinc binding on tau physi-
logical functions (including binding to tubulin) remains
poorly understood. A recent study showing that zinc ions
binding to tau affects its interaction with DNA offers a
first step towards a better understanding of the functional
aspects of Zn-binding [14].

While in many cases zinc acts as an integral component
of the protein structure, it is also known for its ability to
destabilize the structure of a number of proteins (e.g.
NCS-1, TDP-43) [47, 151]. If not the causative agent, zinc
is found implicated in the development of proteinopathies
as a factor favouring aggregation. An impact of zinc bind-
ing on tau aggregation was previously shown in vivo, in
cells and in vitro. Indeed, recent studies demonstrated that
zinc exacerbates tau pathology in a mouse model [28] and
directly regulates tau toxicity in Drosophila tauopathy
model [65]. Moreover, it was shown that high concentra-
tion of zinc dramatically accelerates aggregation of full-
length human tau and increases its toxicity in neuronal
cells [64]. Several studies have addressed the question of
whether zinc impacts on tau aggregation leading to PHF
formation in vitro [64, 65, 102], yet it should be noted that
they were carried out in the presence of artificial aggrega-
tion inductors such as heparin or congo red. Recently it
was shown that these inducers that are classically used to
stimulate PHF formation actually lead to filaments that
have a different structure from those found in vivo [43].
On the contrary, turbidimetry results presented in
EuroTau2018 showed that in the absence of heparin,
zinc is able to induce a temperature-dependent rever-
sible oligomerization of tau [127]. The obtained

amorphous oligomers were not amyloid-like (ThT
negative and no aggregates are observed by EM), and
dissociated instantly following zinc chelation or a
temperature decrease. At this stage it is not clear whether
this newly identified Zn-induced oligomerization mechan-
ism is part of the early stages that may lead to PHF forma-
tion, or it may be part of a concurrent pathway. In any
case, a better understanding of this process at the molecular
level and the role it plays in cell should not be overlooked
when searching for new strategies to fight neurodegenera-
tive diseases.

Of mice and men

Age-related neurodegenerative disorders, including AD are
largely human-specific pathologies. As a matter of fact, the
human brain seems particularly susceptible to develop tau
pathology leading to neurodegeneration [67]. Transgenic
mice are frequently used as animal models for studying
tauopathies and AD despite the fact that they do not readily
develop the full set of neuropathological and/or clinical
phenotypic features observed in the human pathology [96].
Nevertheless, although far from perfect they have been very
useful in dissecting specific molecular pathways involved in
these pathologies as well as for the preclinical evaluation of
potential therapeutic agents. Most of these murine models
require overexpression of human wild-type or mutant tau
in order to develop significant tau pathology. Wild-type
mice do not develop tau fibrillary pathology but mouse tau
can be recruited in a small proportion into aggregates
formed in human tau-overexpressing transgenic brains [9].
Besides the inherent anatomical and cellular differences between the human and mouse brain, one main difference between humans and mice is that the expression of tau isoforms varies in the adult brain. While adult human brain contains almost equal amounts of tau 3R and 4R isoforms, only 4R isoforms are expressed in the adult wild-type mouse brain [10]. Intriguingly, despite this divergence in tau isoform ratios between mice and humans, protein primary sequences are highly conserved between both species (88% identity for the longest tau isoform), particularly within the MTBR (98% identity) [95]. The greatest divergence, however, appears at the N-terminus where humans have a motif spanning residues 18 to 28, which is absent from the mouse tau sequence [121]. Tau amino-terminal region appears to be involved in the formation of the paper-clip conformation under physiological conditions [114].

This 18-28 primate-specific motif of unknown function has recently been reported to mediate tau interaction with a number of neuronal proteins in a species-specific manner [145]. It is worth mentioning that this motif does not include any phosphorylation sites, as the Tyr18 residue long known to be phosphorylated by Fyn tyrosine kinase to mediate tau-plasma membrane interaction [81], remains present in both human and mouse sequences. Interestingly, two closely adjacent, flanking regions to the 18-28 motif in human tau have been described to interact with plasma membrane-binding annexins and thus modulate tau subcellular localization [48].

Prion-like propagation of tau pathology involves the release of tau molecules into the extracellular space, uptake by neighboring cells and seeded aggregation of soluble proteins. Long believed to be a consequence of neuronal death, extracellular tau released from healthy neurons appears however to be a physiological process that might be disrupted in diseased brain [97]. Thus, there is increasing evidence to strongly suggest the involvement of extracellular tau species as the main agent in the propagation of neurofibrillary lesions and spreading of tau toxicity throughout different brain regions in these disorders [52, 107]. On the other hand, a growing body of evidence has accumulated in recent years to demonstrate a crucial role for the amino-terminus in tau aggregation, spreading, dendritic localization and signaling [84]. Actually, overexpression of tau in neuronal and non-neuronal cells leads to increased tau levels in the extracellular medium (reviewed in [118]). Furthermore, the various tau isoforms show different rates of tau release, whereby the N-terminal region appears to contribute to tau release from the cell to the extracellular space [31, 74, 96].

More recently, a full-length human tau lacking the 18-28 motif in the N-terminal region of human tau mentioned above (tau2N4R-Δ18-28) has been shown to be less efficiently secreted compared with wild-type tau when overexpressed in neuronal and non-neuronal

cultured cells [132]. In addition, affinity chromatography analysis looking for proteins specifically interacting with that particular human tau motif identified End Binding (EB) proteins (members of the MTs plus-end tracking protein family) as binding partners. Moreover, while overexpression of EB proteins leads to an increase of tau secretion, EBs downregulation using siRNAs reduced human tau release. The authors suggest a possible cross-talk between tau and EB proteins in distal axons in neurons in which tau would contribute to proper EBs subcellular localization while EBs might favor tau release outside the cell.

Thus, the presence of the human-specific 18-28 motif at the tau N-terminal region might facilitate tau secretion and further propagation of pathology. Studying the underlying mechanisms of tau release will provide further insight into its function in physiological and pathological conditions that may lead to the identification of relevant therapeutic targets and the development of novel therapeutic agents for these devastating disorders.

## A novel panel of tau monoclonal antibodies, rendering new insights in tau structure and fluid diagnosis

A N-terminal truncated fragment of tau, broadly defined as the N-terminal part of tau combined with the proline-rich region and devoid of the repeat domain and C-terminus [16, 99, 130], is now a well-established biomarker that aids in the current set-up of new clinical criteria for AD diagnosis. Advances in MS, such as FLEXITau [88], demonstrate that tau isoforms, defined by specific PTMs, might also help in the development of tau isoform-specific assays for tauopathies [144]. Furthermore, the recent identification of seed-competent soluble tau monomers [101] may lead to tau conformation-specific assays that would be instrumental in tau-specific targeted therapy developments. Thus, set-up of tau molecular assays of antigen-antibody interactions will be essential to advance the use of tau both as fluid marker, and as therapeutic target, in major tauopathies.

Several tau immuno-assays, such as Innotest, Roche Elecsys, Fujirebio Lumipulse, MSD and EuroImmun enzyme-linked immunosorbent assay (ELISA) are currently subjected to harmonization efforts and commutability studies [11]. The EuroImmun ELISA is based on monoclonal tau antibodies raised against tau2N4R expressed in humanized yeast models [128]. The clinical value of this assay has been demonstrated in several studies [34, 147] and the monoclonal antibodies are also used to explore the potential interest of detecting tau circulating in plasma [94, 119]. Equal amounts of 3- and 4-repeat tau are found in cerebral cortex, while expression of tau is roughly two times higher in gray matter compared to white matter and cerebellum. Because assembly of tau is concentration dependent, regional variation in expression could favor its assembly. In cerebrospinal fluid (CSF), 3-
and 4-repeat tau are only a minor fraction of the total protein content and thus isoform-specific immuno-assays require ultra-sensitive technology, such as immuno-PCR. Such assays could potentially aid in the differentiation of 4-repeat tauopathies from other tauopathies [87]. In a renewed effort to isolate conformational tau antibodies, an antibody with a high affinity for exon 3 (the insert N2, Fig. 3) was isolated, named 18F12. While the potential pathological role of N2-containing tau is still subjected to preclinical scientific research [84, 172], the absence of N2-containing tau in the 4-repeat specific tauopathy, amyrophilic grain disease (AGD) [124], suggests that N2-specific tau ELISA for CSF might be able to differentiate AGD from other tauopathies.

Peptide scanning demonstrates that a major determinant of the 18F12 epitope lies in tau insert N1 (Fig. 3). While Western-blot and ELISA results demonstrate an exquisite specificity of 18F12 for N2-specific tau isoforms, peptide mapping (18-mers with an overlap of 16 amino acids) have shown a major antigenic determinant of the 18F12 lies in the C-terminus of N1 (and not in N2). This epitope overlaps with the recently identified epitope of a similar high-affinity antibody, PT18. PT18's epitope was defined as the three last amino acids of N1 and five amino acids of N2 insert in an independent characterization of N2-specific monoclonal antibodies [153], using a slightly modified approach of peptide mapping. Thus N2-specific antibodies most likely require a specific conformation of the N1-N2 junction for optimal recognition of N2 tau isoforms. While further work is needed to understand the conformational aspect of the 18F12 epitope, the fact that exon 3 expression is always associated with exon 2 presence supports a conformational affinity aspect. Since the monoclonal antibody 18F12 had a high affinity, a simple tau ELISA was built based on 18F12 as coating antibody and a N-terminal tau antibody, ADx204, allowing detection of N2-specific tau in CSF. A clinical study in several clinical groups of tauopathies, including AGD, is underway.

Tau is a protein with many PTMs and while all methods to quantify tau have their biases and limitations, widely used sandwich immunoassays are defined by the epitopes of the capturing and detector antibodies used in the assay. Therefore, as our data illustrate, a more precise description of tau antibodies used in diagnostic assays is needed and several studies suggest that this is feasible [27, 89, 136, 169]. Additionally tau protein is not only present as a soluble full-length protein [130], but also as truncated and oligomeric/fibrillar forms. Thus immuno-assays measuring these latter forms should consider epitopes specific for the fragments and target exposed epitopes in case of specific conformations because some epitopes might be buried due to a particular conformation.

To define the added clinical value of novel specific tau immuno-assays with a specific context-of-use, e.g. differentiation of tauopathies, comparing established tau immuno-assays with the novel tau assay will be needed. Finally, depending on the specificity of the novel tau antibodies (e.g. conformational or PTM-dependent), sensitive MS, such as described above (FLEXITau [88], XL-MS [101]), will be needed to validate the specificity of antibodies and assays for its targeted conformation or PTM. Combining technological advances with specific clinical cohort (context-of-use) studies [108, 117] indeed has recently led to exploring the amyloid ratio in plasma as potential surrogate for amyloid Aβ-deposition in preclinical stages of AD.

## Imaging of tau aggregates

Until recently, post-mortem examination of brain tissues was the only means available for the direct evaluation of the changes occurring in the brain of AD and non-AD tauopathy patients. Thanks to molecular neuroimaging techniques such as positron emission tomography (PET) applied with specific radiopharmaceuticals for PHFs (see [134] for a recent review), tau pathology can now be detected, characterized and quantified in the living human brain [26].

Considering the first-generation tau PET ligands, the first fluorine-18 (18F) tracer with tau binding capacity was 18F-FDDNP. However, the compound also binds to β-amyloid and suffered from a lack of selectivity [77]. Meanwhile, more-selective tracers have become available. Carbon-11 (11C) PBB3, allows tau imaging in AD and non-AD tauopathies such as corticobasal syndrome. However, the 11C label is less ideal, as it limits widespread use due to its short half-life of 20 min [137]. Other tau tracers were recently developed such as F18-AV1451 (aka F18-T807, Flortaucipir; Avid Radiopharmaceuticals) or THK5351. F18-AV1451 has demonstrated promising results and showed increased tau binding in AD. Early ex-vivo work demonstrated that F18-AV1451 selectively binds to tangles in post-mortem AD brain tissue [92]. Coupled with PET, F18-AV1451 binding is higher in patients with AD dementia or with mild cognitive impairment than in clinically normal older adults [72]. The first direct comparison of post-mortem tau pathology with in vivo regional F18-AV1451 uptake has just been published [140]. This study is based on a single patient, a man with early onset AD caused by a presenilin mutation. Results showed that in vivo tau tracer retention strongly correlated with both neuritic and intrasomal tau pathology and total tau burden, but not with amyloid plaques, at autopsy.

As expected from neuropathological data [109], tau-PET signal better predicts brain and cognitive dysfunctions than amyloid-PET [120] and the regional distribution of tauopathy closely matches the brain hypometabolism
<figure><img src="image_8.png" /><figcaption>**Fig. 4** Tau PET image in a patient with AD (Mini Mental State Examination= 20/30), demonstrating close association between tau pathology (top) and cerebral glucose metabolism (FDG-PET, bottom). Images were acquired at Saint-Luc University Hospital (UCLouvain, Belgium)</figcaption></figure>

observed using Fluorodeoxyglucose PET [57, 116] (Fig. 4). Tau-PET signal also closely correlates with total tau and 181p-tau concentrations in the CSF [25, 78]. Given the close relationship between tau deposition, impaired cognition and neuronal injury, tau-PET is able to provide significant additive information to clinical diagnosis and amyloid-PET imaging and offers a complementary tool to help in discriminating between different pathologies, and possibly, between different tauopathies. Besides offering in-vivo images, the ability to image the presence and spatial extent of tau deposition also opens the possibility of tracking the progression of tau pathology over time [68] and detecting early changes in cognitively unimpaired individuals [59, 61]. In this respect, it has the potential to serve as a biomarker for disease severity or neurodegeneration. Moreover, the development and efficient usage of tau-directed therapeutics will be highly dependent on the presence or absence of tau and on means to identify those patients best suited for the therapy, so the utility of such disease-modifying drugs are dependent on early and accurate detection of tau. Tau-PET represents as well a non-invasive method to evaluate the efficacy of treatments with the potential to reduce tau load.

At EuroTau 2018, longitudinal tau-PET data from the Harvard Aging Brain study were presented [30, 58]. In clinically normal older individuals, changes in tau-PET signal were shown to correlate with cognitive decline. While an association between change in amyloid and change in tau was also observed, the direct relation between change in amyloid and change in cognition was rather weak [61].

The data presented advocate for sequential changes in preclinical AD from amyloidosis to tauopathy to cognitive deficits. This proof-of-concept study demonstrates the feasibility of tracking tau pathology in normal adults.

Limitations were however reported for some of these investigational first generation tau PET imaging agents concerning off-target binding in several brain regions, such as basal ganglia or choroid plexus. Particularly, off-target binding to Monoamine oxidase A (MAO-A) has been described for F18-AV1451 [155] or to MAO-B for THK5351 [110]. The presence of monoamine oxidases within several brain regions limits the interpretation of PET imaging results with these tracers. MAO-A is mostly only expressed in basal ganglia but MAO-B is expressed in cortex [110]. F18-AV1451 also suffers from off-target binding on neuromelanin present in the choroid plexus of the temporal horn of the lateral ventricles, which makes it difficult to evaluate hippocampal signal properly [80].

The second-generation of tau PET ligands is under development with the objective of breaking the limits of previously reported tau PET agents. These novel second-generation tau tracers currently investigated clinically include F18-RO6958948 (Roche), F18-GTP1 (Genentech), F18-MK-6240 (Merck/Cerveau) and F18-PI-2620 (Life Molecular Imaging). F18-PI-2620 data were presented at EuroTau 2018.

F18-PI-2620 was discovered in a research collaboration between Piramal Imaging (now Life Molecular Imaging) and AC Immune SA. Preclinical pharmacological
studies indicate specific binding of F18-PI-2620 to patho-
logical tau [146]. F18-PI-2620 shows high affinity for
aggregated tau in AD brain homogenate competition-as-
says and PHF preparations. Autoradiography studies using
human brain sections showed specific binding of
F18-PI-2620 in autopsy-confirmed AD tissue sections
from Braak stages I to VI, as well as to tau deposits in PSP
brain tissue. F18-PI-2620 binds to both tau isoforms 3R
and 4R and demonstrates high selectivity over β-amyloid,
α-synuclein, MAO-A and MAO-B. F18-PI-2620 also
showed low off-target binding in competition assays and
autoradiography studies using brain tissue from non-de-
mented controls. Moreover, in microPET imaging studies
in mice and non-human primates, F18-PI-2620 showed
high brain uptake and fast wash-out.

Based on the available promising preclinical data of
F18-PI-2620 the ex-vivo studies have been extended to first
in-human evaluations [146]. In AD subjects, PET images
of F18-PI-2620 showed a tau distribution pattern expected
from typical histopathology tau-spread [22]. In contrast to
the uptake seen with the β-amyloid PET tracer NeuraCeq,
F18-PI-2620 showed an asymmetric uptake pattern in the
temporal lobes, sparring of the motor cortex and asymmet-
ric uptake in the frontal lobe (Fig. 5). Highest signals were
observed in the temporal cortex, extending into the frontal
cortex in the most severe cases. Standard uptake value ra-
tio (SUVr) time curves suggested a plateau of the signal oc-
curring 60–90 min post-injection with resultant SUVrs in
abnormal regions up to four. Clinical data in non-demen-
ted control subjects showed robust initial brain uptake and
fast wash-out from the brain. F18-PI-2620 did not exhibit
an increased tracer uptake in choroid plexus, striatum,
amygdala or other regions of non-demented control
subjects as seen with first generation tau tracers, as well as
no age dependency. Non-invasive quantification of
PI-F18-PI-2620 uptake (SUVr at 60–90 min post injection)

provided significant discrimination between non-demented
control and AD subjects. AD subjects showed significantly
higher uptake than in non-demented control subjects in
temporal lobe, parietal and cingulate cortex. Moreover, ex-
cellent test-retest variability has been demonstrated and
confirmed the utility of F18-PI-2620 to evaluate change of
tau deposition in longitudinal studies.

Given the role of tau protein in the pathology of AD
and other non-AD tauopathies, neuroimaging tau PET
biomarker offers the potential to improve our under-
standing of the pathological process in AD and other
tauopathies. Beyond the major progresses that such im-
aging tool offers for research on these pathologies, the
ability to image tau in in vivo brain brings relevant clin-
ical perspectives.

PET imaging appears as a useful tool for detecting the
presence and spatial extent of tau deposition in in-vivo
brains and offers the potential to improve our understand-
ing of the molecular mechanism of neurofibrillary dege-
neration, to predict and track disease progression and to
accelerate the development of rational therapies for AD
and non-AD tauopathies.

Conclusions

Recently, significant advances have been made in under-
standing tau structure and aggregation. The recent inte-
rest in immuno-therapies targeted against tau [69] require
a good definition of what should be targeted by the
assayed antibodies. Many disappointing trials could prob-
ably be avoided from a better definition of tau structure
and related (dys)functions. Similarly, to be able to relate
tau detection to a specific form is essential. Many studies
still rely on the good old AT8 antibody to assess the level
of tau pathology in cells or tissues. In this regard, imaging
has also offered impressive progress that will be critical to
assess any results coming from therapeutic intervention

<figure><img src="image_9.png" /><figcaption>**Fig. 5** Comparison of tracer uptake patterns of F18-PI-2620 targeting tau and Neuraceq targeting β-amyloid plaques</figcaption></figure>
on the tau pathway. In this field, it will also be crucial to
know what is traced.

While instrumentation advancements have allowed re-
cent breakthroughs in structural biology of amyloids, there
are still major fundamental challenges to solve. For
example, what are the molecular factors that determine the
convergence toward a given strain/structure? How can one
reproduce the brain-derived filament structures with re-
combinant protein? While cryoEM has shown that a given
tauopathy is characterized by a specific aggregate structure,
it remains to be shown that a given structure is sufficient
to trigger a specific disease. In other words, do the tau
aggregate structures carry all the pathological information,
as the prion denomination suggests, or are there other sys-
temic factors required?

In addition, the causal relationship between tau hyper-
phosphorylation and aggregation in neuropathology re-
mains to be demonstrated and to date, there are only a
limited number of studies that have explored this relation-
ship. A better definition of the pattern(s) of tau phosphory-
lation that might affect its conformation and lead to the
aggregation path is worth the efforts, as it could help both
diagnostic and therapeutic development by defining the
species of tau that could be considered as targets for
immune-detection or immune-intervention.

All these questions can only be addressed by bringing
together the various approaches, such as NMR for fle-
xible Tau forms and Cryo-EM for the most rigid forms
or fluid immuno-diagnosis coupled to brain imaging re-
search. The EuroTau meeting will continue to provide
such opportunities.

Abbreviations

1 N: First insert; 11C: Carbon-11; 18F: Fluorine-18; 2 N: Second insert;
3R: Three repeat; 4R: Four repeat; AD: Alzheimer's disease; AGD: Argyrophilic
grain disease; CD: Circular dichroism; cryo-EM: Cryo-electron microscopy;
CSF: Cerebrospinal fluid; EB protein: End-binding protein; ELISA: Enzyme-
linked immunosorbent assay; EM: Transmission electron microscopy; EPR
spectroscopy: Electron paramagnetic spectroscopy; IDP: Intrinsically
disordered protein; ITC: Isothermal titration calorimetry; MRI: Magnetic
resonance imaging; MS: Mass spectrometry; MTBR: Microtubule binding
region; MTs: Microtubules; NFTs: Neurofibrillary tangles; NMR: Nuclear
Magnetic resonance Spectroscopy; PET: Positron emission tomography;
PHF6*: PHF6\* (275VQIINK<sub>280</sub>) and PHF6 (306VQIVYK<sub>311</sub>) hexa-peptide se-
quences; PHFs: Paired-helical filaments; PiD: Pick's disease; pSer/
pThr: Phospho-serine/phospho-threonine; PSP: Progressive Supranuclear
Palsy; PTMs: Post translational modifications; SFs: Straight Filaments;
sSNMR: Solid-state NMR; SUVr: Standard uptake value ratio; ThT: ThioflavinT

Acknowledgements

The authors acknowledge Prof. Martin Margittai and Prof. Eckhard Mandelkow for fruitful discussions. The EuroTau 2018 meeting was sponsored by CUB BioPharma, Janssen Pharmaceutical Companies, Sanofi, Axon Neuroscience, Servier, Quanterix, Proteome Sciences and Proteintech. It was also supported by French and Spanish academic funds from University of Lille, SFR DN2M, LabEx DISTALZ, LICEND, and CIBERNED.

Authors' contributions

All authors participated in writing, read and approved the final manuscript.

Competing interests

JW declares that he is cofounder and shareholder of reMYND nv (Leuven, Belgium) and ADxNeurosciences (Ghent, Belgium). EV declares that he is cofounder and employee of ADxNeurosciences (Ghent, Belgium). AP is a Life Molecular Imaging (Berlin, Germany). LB declares that he is cofounder and shareholder of SPQI (Lille, France). Other authors declare that they have no competing interests.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of chemistry and biochemistry, University of California Santa Barbara, Santa Barbara, CA 93106, USA. ²Dementia Research group, School of Life Sciences, University of Sussex, Falmer, E Sussex BN1 9QG, UK. ³Chemistry Department, Science College, Mustansiriyah University, Baghdad, Iraq.

⁴Aix-Marseille University, CNRS, INP, Inst Neurophysiopathol, Fac Pharm, Marseille, France. ⁵University of Lille, CNRS, UMR8576, 59000 Lille, France.

⁶Functional Biology, KU Leuven, Kasteelpark Arenberg 31, Box 2433, 3001 Heverlee, Belgium. ⁷Pharmabs, KU Leuven, Herestraat 49, box 820, B 3000 Leuven, Belgium. ⁸ADx NeuroSciences NV, Technologiepark Zwijnaarde 94, 9052 Ghent, Belgium. ⁹Life Molecular Imaging, Berlin, Germany. ¹⁰Neurology Department, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200 Brussels, Belgium. ¹¹Gordon Center for Medical Imaging, Radiology Department, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ¹²CIBERNED (Network Center for Biomedical Research in Neurodegenerative Diseases), Madrid, Spain. ¹³CIEN Foundation, Queen Sofia Foundation Alzheimer Center, Madrid, Spain. ¹⁴University of Lille, Inserm, CHU-Lille, UMR1172, 59000 Lille, France.

Received: 31 December 2018 Accepted: 20 February 2019

Published online: 01 March 2019

References

1. Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, Binder LI (2000) C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 113(Pt 21):3737-3745

2. Ait-Bouziad N, Lv G, Mahul-Mellier A-L, Xiao S, Zorludemir G, Eliezer D, Walz T, Lashuel HA (2017) Discovery and characterization of stable and toxic tau/ phospholipid oligomeric complexes. Nat Commun 8:1678. https://doi.org/10.1038/s41467-017-01575-4

3. Al-Hilaly YK, Pollack SJ, Rickard JE, Simpson M, Raulin A-C, Baddeley T, Schellenberger P, Storey JMD, Harrington CR, Wischik CM, Serpell LC (2018) Cysteine-independent inhibition of Alzheimer's disease-like paired helical filament assembly by Leuco-Methylthioninium (LMT). J Mol Biol 430:4119-4131. https://doi.org/10.1016/j.jmb.2018.08.010

4. Al-Hilaly YK, Pollack SJ, Vadukul DM, Citossi F, Rickard JE, Simpson M, Storey JMD, Harrington CR, Wischik CM, Serpell LC (2017) Alzheimer's disease-like paired helical filament assembly from truncated tau protein is independent of disulfide crosslinking. J Mol Biol 429:3650-3665. https://doi.org/10.1016/j.jmb.2017.09.007

5. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K (2001) Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U A 98:6923-6928

6. Alonso AC, Grundke-Iqbal I, Iqbal K (1996) Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2:783-787

7. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U A 91:5562-5566

8. Ambadipudi S, Biernat J, Riedel D, Mandelkow E, Zweckstetter M (2017) Liquid-liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein tau. Nat Commun 8:275. https://doi.org/10.1038/s41467-017-00480-0

9. Ando K, Leroy K, Héraud C, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion J-P (2011) Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am J Pathol 178:803-816. https://doi.org/10.1016/j.ajpath.2010.10.034
10. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde Y-A, Duff K, Davies P (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86:582-590

11. Andreasson U, Kuhlmann J, Pannee J, Umek RM, Stops E, Vanderstichele H, Matzen A, Vandijck M, Dauwe M, Leinenbach A, Rutz S, Portelius E, Zegers I, Zetterberg H, Blennow K (2018) Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements. Clin Chem Lab Med 56:2058-2066. https://doi.org/10.1515/cclm-2018-0147

12. Andronesi OC, von Bergen M, Biernat J, Seidel K, Griesinger C, Mandelkow E, Baldus M (2008) Characterization of Alzheimer's-like paired helical filaments from the core domain of tau protein using solid-state NMR spectroscopy. J Am Chem Soc 130:5922-5928. https://doi.org/10.1021/ja7100517

13. Armstrong RA, Lantos PL, Cairns NJ (2008) What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease? Neuropathology 28:351-365. https://doi.org/10.1111/j.1440-1789.2008.00916.x

14. Asadollahi K, Riazi G, Rabbani Chadegani A, Rafiee S (2018) DNA-binding mode transition of tau in the presence of zinc ions. J Biomol Struct Dyn 36: 1925-1933. https://doi.org/10.1080/07391102.2017.1343684

15. Barghorn S, Davies P, Mandelkow E (2004) Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain. Biochemistry 43:1694-1703. https://doi.org/10.1021/bi0357006

16. Barthélemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, Buée L, Gabelle A, Junot C, Lehmann S, Becher F (2016) Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity. J Proteome Res 15:667-676. https://doi.org/10.1021/acs.jproteome.5b01001

17. Benhelli-Mokrani H, Mansuroglu Z, Chauderlier A, Albaud B, Gentien D, Sommer S, Schirmer C, Laqueuvre L, Josse T, Buée L, Lefebvre B, Galas M-C, Souès S, Bonnefoy E (2018) Genome-wide identification of genic and intergenic neuronal DNA regions bound by tau protein under physiological and stress conditions. Nucleic Acids Res 46:11405-11422. https://doi.org/10.1093/nar/gky929

18. Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA (2003) Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A 100:9034-9038. https://doi.org/10.1073/pnas.1530287100

19. Bibow S, Mukrasch MD, Chinnathambi S, Biernat J, Griesinger C, Mandelkow E, Zweckstetter M (2011) The dynamic structure of filamentous tau. Angew Chem Int Ed Engl 50:11520-11524. https://doi.org/10.1002/anie.201105493

20. Bourré G, Cantrelle F-X, Kamah A, Chambraud B, Landrieu I, Smet-Nocca C (2018) Direct crosstalk between A-GlcNAcylation and phosphorylation of tau protein investigated by NMR spectroscopy. Front Endocrinol 9:595. https://doi.org/10.3389/fendo.2018.00595

21. Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16:271-278 discussion 278-84

22. Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 19:351-357

23. Brion JP, Flament-Durand J, Dustin P (1986) Alzheimer's disease and tau proteins. Lancet 2:1098 doi: S0140-6736(86)90495-2

24. Carmel G, Mager EM, Binder LI, Kuret J (1996) The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem 271:32789-32795

25. Chhatwal JP, Schultz AP, Marshall GA, Boot B, Gomez-Isla T, Dumurgier J, LaPoint M, Scherzer C, Roe AD, Hyman BT, Sperling RA, Johnson KA (2016) Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology 87:920-926. https://doi.org/10.1212/WNL.0000000000003050

26. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su M-Y, Elizarov A, Kolb HC (2014) Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis JAD 38:171-184. https://doi.org/10.3233/JAD-130098

27. Chukwu JE, Pedersen JT, Pedersen LØ, Volbracht C, Sigurdsson EM, Kong X-P (2018) Tau antibody structure reveals a molecular switch defining a pathological conformation of the tau protein. Sci Rep 8:6209. https://doi.org/10.1038/s41598-018-24276-4

28. Craven KM, Kochen WR, Hernandez CM, Flinn JM (2018) Zinc exacerbates tau pathology in a tau mouse model. J Alzheimers Dis JAD 64:617-630. https://doi.org/10.3233/JAD-180151

29. Daebel V, Chinnathambi S, Biernat J, Schwalbe M, Habenstein B, Loquet A, Akoury E, Tepper K, Müller H, Baldus M, Griesinger C, Zweckstetter M,

Mandelkow E, Vijayan V, Lange A (2012) β-Sheet core of tau paired helical filaments revealed by solid-state NMR. J Am Chem Soc 134:13982-13989. https://doi.org/10.1021/ja305470p

30. Dagley A, LaPoint M, Huijbers W, Hedden T, McLaren DG, Chatwal JP, Papp KV, Amariglio RE, Blacker D, Rentz DM, Johnson KA, Sperling RA, Schultz AP (2017) Harvard aging brain study: dataset and accessibility. Neurolimage 144: 255-258. https://doi.org/10.1016/j.neuroimage.2015.03.069

31. Dai C-L, Tung YC, Liu F, Gong C-X, Iqbal K (2017) Tau passive immunization inhibits not only tau but also Aβ pathology. Alzheimers Res Ther 9:1. https://doi.org/10.1186/s13195-016-0227-5

32. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT (2010) Caspase activation precedes and leads to tangles. Nature 464:1201-1204. https://doi.org/10.1038/nature08890

33. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73:685-697. https://doi.org/10.1016/j.neuron.2011.11.033

34. De Vos A, Struyfs H, Jacobs D, Fransen E, Klewansky T, De Roeck E, Robberecht C, Van Broeckhoven C, Duyckaerts C, Engelborghs S, Vanmechemel E (2016) The cerebrospinal fluid Neurogrin/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer's disease. J Alzheimers Dis JAD 53:1523-1538. https://doi.org/10.3233/JAD-160227

35. Despres C, Byrne C, Qi H, Cantrelle F-X, Huvent I, Chambraud B, Baulieu E-E, Jacquot Y, Landrieu I, Lippens G, Smet-Nocca C (2017) Identification of the tau phosphorylation pattern that drives its aggregation. Proc Natl Acad Sci U S A 114:9080-9085. https://doi.org/10.1073/pnas.1708448114

36. Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsu C, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee A, Ryder MI, Potempa B, Mydel P, Hellvard A, Adamowicz K, Hasturk H, Walker GD, Reynolds EC, Faull RLM, Curtis MA, Dragunow M, Potempa J (2019) Porphyromonas gingivalis in Alzheimer's disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 5:eaaau3333. https://doi.org/10.1126/sciadv.aau3333

37. Dujardin S, Bégard S, Caillierez R, Lachaud C, Carrier S, Lieger S, Gonzalez JA, Deramecourt V, Déglon N, Maurage C-A, Frosch MP, Hyman BT, Colin M, Buée L (2018) Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathol Commun 6:132. https://doi.org/10.1186/s40478-018-0637-7

38. Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y, Cook C, Miller SJ, Dujardin S, Amaral AS, Grima JC, Bennett RE, Tepper K, DeTure M, Vanderburg CR, Corjuc BT, DeVos SL, Gonzalez JA, Chew J, Vidensky S, Gage FH, Mertens J, Troncoso J, Mandelkow E, Salvatella X, Lim RYH, Petrucelli L, Wegmann S, Rothstein JD, Hyman BT (2018) Tau protein disrupts nucleocytoplasmic transport in Alzheimer's disease. Neuron 99:925-940.e7. https://doi.org/10.1016/j.neuron.2018.07.039

39. Eschmann NA, Georgieva ER, Ganguly P, Borbat PP, Rappaport MD, Akdogan Y, Freed JH, Shea J-E, Han S (2017) Signature of an aggregation-prone conformation of tau. Sci Rep 7:44739. https://doi.org/10.1038/srep44739

40. Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R, Crowther RA, Ghetti B, Scheres SHW, Goedert M (2018) Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature 561: 137-140. https://doi.org/10.1038/s41586-018-0454-y

41. Falcon B, Zhang W, Schweighauser M, Murzin AG, Vidal R, Garringer HJ, Ghetti B, Scheres SHW, Goedert M (2018) Tau filaments from multiple cases of sporadic and inherited Alzheimer's disease adopt a common fold. Acta Neuropathol (Berl) 136:699-708. https://doi.org/10.1007/s00401-018-1914-z

42. Fichou Y, Lin Y, Rauch JN, Vigers M, Zeng Z, Srivastava M, Keller TJ, Freed JH, Kosik KS, Han S (2018) Cofactors are essential constituents of stable and seeding-active tau fibrils. Proc Natl Acad Sci. https://doi.org/10.1073/pnas.1810058115

43. Fichou Y, Vigers M, Goring AK, Eschmann NA, Han S (2018) Heparin-induced tau filaments are structurally heterogeneous and differ from Alzheimer's disease filaments. Chem Commun 54:4573-4576. https://doi.org/10.1039/C8CC01355A

44. Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, Scheres SHW (2017) Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 547:185-190. https://doi.org/10.1038/nature23002

45. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles
in Alzheimer's disease. Proc Natl Acad Sci U S A 100:10032-10037. https://doi.org/10.1073/pnas.1630428100

46. Gandhi NS, Landrieu I, Byrne C, Kukic P, Amniai L, Cantrelle F-X, Wieruszeski J-M, Mancera RL, Jacquot Y, Lippens G (2015) A phosphorylation-induced turn defines the Alzheimer's disease AT8 antibody epitope on the tau protein. Angew Chem Int Ed Engl 54:6819-6823. https://doi.org/10.1002/anie.201501898

47. Garnier C, Devred F, Byrne D, Puppo R, Roman AY, Malesinski S, Golovin AV, Lebrun R, Ninkina NN, Tsvetkov PO (2017) Zinc binding to RNA recognition motif of TDP-43 induces the formation of amyloid-like aggregates. Sci Rep 7:6812. https://doi.org/10.1038/s41598-017-07215-7

48. Gauthier-Kemper A, Suárez Alonso M, Sündermann F, Niewidok B, Fernandez M-P, Bakota L, Heinisch JJ, Brandt R (2018) Annexins A2 and A6 interact with the extreme N terminus of tau and thereby contribute to tau's axonal localization. J Biol Chem 293:8065-8076. https://doi.org/10.1074/jbc.RA117.000490

49. Gigant B, Landrieu J, Fauquant C, Barbier P, Huvent I, Wieruszeski J-M, Knossow M, Lippens G (2014) Mechanism of tau-promoted microtubule assembly as probed by NMR spectroscopy. J Am Chem Soc 136:12615-12623. https://doi.org/10.1021/ja504864m

50. Ginsberg SD, Galvin JE, Chiu TS, Lee VM, Masliah E, Trojanowski JQ (1998) RNA sequestration to pathological lesions of neurodegenerative diseases. Acta Neuropathol (Berl) 96:487-494

51. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA (1996) Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383:550-553. https://doi.org/10.1038/383550a0

52. Goedert M, Spillantini MG (2017) Propagation of tau aggregates. Mol Brain 10:18. https://doi.org/10.1186/s13041-017-0298-7

53. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3: 519-526 doi: 0896-6273(89)90210-9

54. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261:6084-6089

55. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83:4913-4917

56. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 71:2465-2476

57. Hanseeuw BJ, Betensky RA, Schultz AP, Papp KV, Mornino EC, Sepulcre J, Bark JS, Cosio DM, LaPoint M, Chhatwal JP, Rentz DM, Sperling RA, Johnson KA (2017) Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol 81:583-596. https://doi.org/10.1002/ana.24910

58. Hanseeuw BJ, Mornino BC, Becker A, Sepulcre J, Papp KV, Schultz AP, Jacobs HI, Cosio DM, Chhatwal JP, Sperling RA, Johnson K (2017) Longitudinal tau accumulation is associated with cognitive decline in normal elderly. Alzheimers Dement J Alzheimers Assoc 13:P134-P136 doi: 10.1016/j.jalz.2017.06.2556

59. Hansson O, Mornino EC (2018) Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials? Brain J Neurol 141:1241-1244. https://doi.org/10.1093/brain/awy065

60. Harrington CR, Mukaetova-Ladinska EB, Hills R, Edwards PC, Montejo de Garcini E, Novak M, Wischik CM (1991) Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease. Proc Natl Acad Sci U S A 88:5842-5846

61. Harrison TM, La Joie R, Maass A, Baker SL, Swinnerton K, Fenton L, Mellinger TJ, Edwards L, Pham J, Miller BL, Rabinovici GD, Jagust WJ (2019) Longitudinal tau accumulation and atrophy in aging and alzheimer disease. Ann Neurol 85:229-240. https://doi.org/10.1002/ana.25406

62. Hasegawa H, Holm L (2009) Advances and pitfalls of protein structural alignment. Curr Opin Struct Biol 19:341-348. https://doi.org/10.1016/j.sbi.2009.04.003

63. Himmler A, Drechsel D, Kirschner MW, Martin DW Jr (1989) Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol 9:1381-1388

64. Hu J-Y, Zhang D-L, Liu X-L, Li X-S, Cheng X-Q, Chen J, Du H-N, Liang Y (2017) Pathological concentration of zinc dramatically accelerates abnormal aggregation of full-length human tau and thereby significantly increases tau toxicity in neuronal cells. Biochim Biophys Acta Mol basis Dis 1863:414-427. https://doi.org/10.1016/j.bbadis.2016.11.022

65. Huang Y, Wu Z, Cao Y, Lang M, Lu B, Zhou B (2014) Zinc binding directly regulates tau toxicity independent of tau hyperphosphorylation. Cell Rep 8: 831-842. https://doi.org/10.1016/j.celrep.2014.06.047

66. Huvent I, Kamah A, Cantrelle F-X, Barois N, Slomianny C, Smet-Nocca C, Landrieu I, Lippens G (2014) A functional fragment of tau forms fibers without the need for an intermolecular cysteine bridge. Biochem Biophys Res Commun 445:299-303. https://doi.org/10.1016/j.bbrc.2014.01.161

67. Iqbal K, Alonso AC, Gong CX, Khatoon S, Singh TJ, Grundke-Iqbal I (1994) Mechanism of neurofibrillary degeneration in Alzheimer's disease. Mol Neurobiol 9:119-123

68. Jack CR, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, Weigand SD, Therneau TM, Knopman DS, Gunter JL, Jones DT, Graff-Radford J, Kantarci K, Roberts RO, Mielke MM, Machulda MM, Petersen RC (2018) Longitudinal tau PET in ageing and Alzheimer's disease. Brain J Neurol 141:1517-1528. https://doi.org/10.1093/brain/awy059

69. Jadvah S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, Buée L, Zilka N (2019) A walk through tau therapeutic strategies. Acta Neuropathol Commun 7:22. https://doi.org/10.1186/s40478-019-0664-z

70. Jakes R, Novak M, Davison M, Wischik CM (1991) Identification of 3- and 4-repeat tau isoforms within the PHF in Alzheimer's disease. EMBO J 10:2725-2729

71. Jeganathan S, Hascher A, Chinnathambi S, Biernat J, Mandelkow EM, Mandelkow E (2008) Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of tau and generates a pathological (MC-1) conformation. J Biol Chem 283:32066-32076. https://doi.org/10.1074/jbc.M805300200

72. Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mornino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79: 110-119. https://doi.org/10.1002/ana.24546

73. Kadavath H, Hofele RV, Biernat J, Kumar S, Tepper K, Urlaub H, Mandelkow E, Zweckstetter M (2015) Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci U S A 112: 7501-7506. https://doi.org/10.1073/pnas.1504081112

74. Karch CM, Jeng AT, Goate AM (2012) Extracellular tau levels are influenced by variability in tau that is associated with tauopathies. J Biol Chem 287: 42751-42762. https://doi.org/10.1074/jbc.M112.380642

75. Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, Miller TM, Diamond MI (2016) Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron 92:796-812. https://doi.org/10.1016/j.neuron.2016.09.055

76. Kellogg EH, Hejab NMA, Poepsel S, Downing KH, DiMaio F, Nogales E (2018) Near-atomic model of microtubule-tau interactions. Science 360:1242-1246. https://doi.org/10.1126/science.aat1780

77. Kepe V, Bordelon Y, Boxer A, Huang S-C, Liu J, Thiede FC, Mazziotta JC, Mendez MF, Donoghue N, Small GW, Barrio JR (2013) PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis JAD 36:145-153. https://doi.org/10.3233/JAD-130032

78. La Joie R, Bejanin A, Fagan AM, Ayakta N, Baker SL, Bourakova V, Boxer AL, Cha J, Karydas A, Jerome G, Maass A, Mensing A, Miller ZA, O'Neil JP, Pham J, Rosen HJ, Tsai R, Visani AV, Miller BL, Jagust WJ, Rabinovici GD (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290. https://doi.org/10.1212/WNL.0000000000004860

79. Landau M, Sawaya MR, Faull KF, Laganowsky A, Jiang L, Sievers SA, Liu J, Barrio JR, Eisenberg D (2011) Towards a pharmacophore for amyloid. PLoS Biol 9:e1001080. https://doi.org/10.1371/journal.pbio.1001080

80. Lee CM, Jacobs HIL, Marquéi M, Becker JA, Andrea NV, Jin DS, Schultz AP, Frosch MP, Gómez-Isla T, Sperling RA, Johnson KA (2018) 18F-Flortaucipir binding in choroid plexus: related to race and Hippocampus signal. J Alzheimers Dis JAD 62:1691-1702. https://doi.org/10.3233/JAD-170840

81. Lee G, Cowan N, Kirschner M (1988) The primary structure and heterogeneity of tau protein from mouse brain. Science 239:285-288
82. Li B, Chohan MO, Grundke-Iqbal I, Iqbal K (2007) Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. *Acta Neuropathol* (Berl) 113:501–511. https://doi.org/10.1007/s00401-007-0207-8

83. Li T, Braunstein KE, Zhang J, Lau A, Sibener L, Deeble C, Wong PC (2016) The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model. *Nat Commun* 7:12082. https://doi.org/10.1038/ncomms12082

84. Liu C, Song X, Nisbet R, Götz J (2016) Co-immunoprecipitation with tau isoform-specific antibodies reveals distinct protein interactions and highlights a putative role for 2N tau in disease. *J Biol Chem* 291:8173–8188. https://doi.org/10.1074/jbc.M115.641902

85. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong C-X (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. *Proc Natl Acad Sci U S A* 101:10804–10809. https://doi.org/10.1073/pnas.0400348101

86. Liu F, Shi J, Tanimukai H, Gu J, Gu J, Grundke-Iqbal I, Iqbal K, Gong C-X (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. *Brain J Neurol* 132:1820–1832. https://doi.org/10.1093/brain/awp099

87. Luk C, Compta Y, Magdalinin N, Martí MJ, Hondamuni G, Zetterberg H, Blennow K, Constantinescu R, Pijnenburg Y, Mollenhauer B, Trenkwalder C, Van Swieten J, Chiu WZ, Borroni B, Cámara A, Cheshire P, Williams DR, Lees AJ, de Silva R (2012) Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. *J Neurochem* 123:396–405. https://doi.org/10.1111/j.1471-4159.2012.07911.x

88. Mair W, Muntel J, Tepper K, Tang S, Biernat J, Seeley WW, Kosik KS, Mandelkow E, Steen H, Steen JA (2016) FLEXITau: quantifying post-translational modifications of tau protein in vitro and in human disease. *Anal Chem* 88:3704–3714. https://doi.org/10.1021/acs.analchem.5b04509

89. Malia TJ, Teplyakov A, Ernst R, Wu S-J, Lacy ER, Liu X, Vandermeeren M, Mercken M, Luo J, Sweet RW, Gilliland GL (2016) Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8. *Proteins* 84:427–434. https://doi.org/10.1002/prot.24988

90. Malki I, Cantrelle F-X, Sottejeau Y, Lippens G, Lambert J-C, Landrieu I (2017) Regulation of the interaction between the neuronal BIN1 isoform 1 and tau proteins - role of the SH3 domain. *FEBS J* 284:3218–3229. https://doi.org/10.1111/febs.14185

91. Margittai M, Langen R (2004) Template-assisted filament growth by parallel stacking of tau. *Proc Natl Acad Sci U S A* 101:10278–10283. https://doi.org/10.1073/pnas.0401911101

92. Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, Gómez-Isla T (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. *Ann Neurol* 78:787–800. https://doi.org/10.1002/ana.24517

93. Martinho M, Allegro D, Huvent I, Chabaud C, Etienne E, Kovacic H, Guigliarelli B, Peyrot V, Landrieu I, Belle V, Barbier P (2018) Two tau binding sites on tubulin revealed by thiol-disulfide exchanges. *Sci Rep* 8:13846. https://doi.org/10.1038/s41598-018-32096-9

94. Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K, Investigators ADNI (2016) Plasma tau in Alzheimer disease. *Neurology* 87:1827–1835. https://doi.org/10.1212/WNL.00000000000003246

95. McMillan P, Korvatska E, Poorkaj P, Evstafjeva Z, Robinson L, Greenup L, Leverenz J, Schellenberg GD, D'Souza I (2008) Tau isoform regulation is region- and cell-specific in mouse brain. *J Comp Neurol* 511:788–803. https://doi.org/10.1002/cne.21867

96. Medina M, Avila J (2014) The need for better AD animal models. *Front Pharmacol* 5:227. https://doi.org/10.3389/fphar.2014.00227

97. Medina M, Hernández F, Avila J (2016) New features about tau function and dysfunction. *Biomolecules* 6. https://doi.org/10.3390/biom6020021

98. Mena R, Edwards P, Pérez-Olvera O, Wischik CM (1995) Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease. *Acta Neuropathol* (Berl) 89:50–56

99. Meredith JE, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF (2013) Characterization of novel CSF tau and

ptau biomarkers for Alzheimer's disease. *PLoS One* 8:e76523. https://doi.org/10.1371/journal.pone.0076523

100. Meyer V, Holden MR, Weismiller HA, Eaton GR, Eaton SS, Margittai M (2016) Fracture and growth are competing forces determining the fate of conformers in tau fibril populations. *J Biol Chem* 291:12271–12281. https://doi.org/10.1074/jbc.M116.715557

101. Mirbaha H, Chen D, Morazova OA, Ruff KM, Sharma AM, Liu X, Goodarzi M, Pappu RV, Colby DW, Mirzaei H, Joachimiak LA, Diamond MI (2018) Inert and seed-competent tau monomers suggest structural origins of aggregation. *eLife* 7:e36584. doi: https://doi.org/10.7554/eLife.36584

102. Mo Z-Y, Zhu Y-Z, Zhu H-L, Fan J-B, Chen J, Liang Y (2009) Low micromolar zinc accelerates the fibrillization of human tau via bridging of Cys-291 and Cys-322. *J Biol Chem* 284:34648–34657. https://doi.org/10.1074/jbc.M109.058883

103. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Watanabe A, Titani K, Ihara Y (1995) Hyperphosphorylation of tau in PHF. *Neurobiol Aging* 16:365–371 discussion 371-80

104. Morris DR, Levenson CW (2017) Neurotoxicity of zinc. *Adv Neurobiol* 18: 303–312. https://doi.org/10.1007/978-3-319-60189-2_15

105. Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame AL, Mucke L (2015) Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. *Nat Neurosci* 18:1183–1189. https://doi.org/10.1038/nn.4067nn.4067

106. Moussaud S, Jones DR, Moussaud-Lamodière EL, Delenclos M, Ross OA, McLean PJ (2014) Alpha-synuclein and tau: teammates in neurodegeneration? *Mol Neurodegener* 9:43. https://doi.org/10.1186/1750-1326-9-43

107. Mudher A, Brion J-P, Avila J, Medina M, Buée L (2017) EuroTau: towing scientists to tau without tautology. *Acta Neuropathol Commun* 5:90. https://doi.org/10.1186/s40478-017-0491-z

108. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li Q-X, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K (2018) High performance plasma amyloid-β biomarkers for Alzheimer's disease. *Nature* 554:249–254. https://doi.org/10.1038/nature25456

109. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J Neuropathol Exp Neurol* 71:362–381. https://doi.org/10.1097/NEN.0b013e31825018f7

110. Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot M-C, Guo Q, Harada R, Comley RA, Massarweh G, Soucy J-P, Okamura N, Gauthier S, Rosa-Neto P (2017) Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. *Alzheimers Res Ther* 9:25. https://doi.org/10.1186/s13195-017-0253-y

111. Nizynski B, Nieznanska H, Dec R, Boyko S, Dzvolak W, Nieznanski K (2018) Amyloidogenic cross-seeding of tau protein: transient emergence of structural variants of fibrils. *PLoS One* 13:e0201182. https://doi.org/10.1371/journal.pone.0201182

112. Novak M, Kabat J, Wischik CM (1993) Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. *EMBO J* 12:365–370

113. Novak P, Cehlar O, Skrabana R, Novak M (2018) Tau conformation as a target for disease-modifying therapy: the role of truncation. *J Alzheimers Dis* 64:S535–S546. https://doi.org/10.3233/JAD-179942

114. Ojo JO, Mouzon BC, Crawford F (2016) Repetitive head trauma, chronic traumatic encephalopathy and tau: challenges in translating from mice to men. *Exp Neurol* 275(Pt 3):389–404. https://doi.org/10.1016/j.expneurol.2015.06.003

115. Oroz J, Chang BJ, Wysoczanski P, Lee C-T, Pérez-Lara A, Chakraborty P, Hofele RV, Baker JD, Blair LJ, Biernat J, Urlaub H, Mandelkow E, Dickey CA, Zweckstetter M (2018) Structure and pro-toxic mechanism of the human Hsp90/PPIase/tau complex. *Nat Commun* 9:4532. https://doi.org/10.1038/s41467-018-06880-0

116. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. *Brain J Neurol* 139:1551–1567. https://doi.org/10.1093/brain/aww027
117. Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ (2017) Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13:841–849. https://doi.org/10.1016/j.jalz.2017.06.2266

118. Pérez M, Medina M, Hernández F, Avila J (2018) Secretion of full-length tau or tau fragments in cell culture models. Propagation of tau in vivo and in vitro. *Biomol Concepts* 9:1–11. https://doi.org/10.1515/bmc-2018-0001

119. Pérez-Ruiz E, Decrop D, Ven K, Tripodi L, Leirs K, Rosseels J, van de Wouwer M, Geukens N, De Vos A, Vanmechelen E, Winderickx J, Lammertyn J, Spasic D (2018) Digital ELISA for the quantification of attomolar concentrations of Alzheimer's disease biomarker protein tau in biological samples. *Anal Chim Acta* 1015:74–81. https://doi.org/10.1016/j.laca.2018.02.011

120. Pontecorvo MJ, Devous MD, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA, 18F-AV-1451-A05 investigators (2017) Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. *Brain J Neurol* 140:748–763. https://doi.org/10.1093/brain/aww334

121. Poorkaj P, Kas A, D'Souza I, Zhou Y, Pham Q, Stone M, Olson MV, Schellenberg GD (2001) A genomic sequence analysis of the mouse and human microtubule-associated protein tau. *Mamm Genome* 12:700–712

122. Qi H, Cantrelle F-X, Benhelli-Mokrani H, Smet-Nocca C, Buée L, Lippens G, Bonnefoy E, Galas M-C, Landrieu I (2015) Nuclear magnetic resonance spectroscopy characterization of interaction of tau with DNA and its regulation by phosphorylation. *Biochemistry* 54:1525–1533. https://doi.org/10.1021/bi5014613

123. Qi H, Prabakaran S, Cantrelle F-X, Chambraud B, Gunawardena J, Lippens G, Landrieu I (2016) Characterization of neuronal tau protein as a target of extracellular signal-regulated kinase. *J Biol Chem* 291:7742–7753. https://doi.org/10.1074/jbc.M115.700914

124. Rábano A, Cuadros R, Calero M, Hernández F, Avila J (2013) Specific profile of tau isoforms in argyrophilic grain disease. *J Exp Neurosci* 7:51–59. https://doi.org/10.4137/JEN.S12202

125. Rodríguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, Jiang L, Arbing MA, Nannenga BL, Hattne J, Whitelegge J, Brewster AS, Messerschmidt M, Boutet S, Sauter NK, Gonen T, Eisenberg DS (2015) Structure of the toxic core of α-synuclein from invisible crystals. *Nature* 525:486–490. https://doi.org/10.1038/nature15368

126. Rodríguez-Martín T, Cuchillo-Ibáñez I, Noble W, Nyenya F, Anderton BH, Hanger DP (2013) Tau phosphorylation affects its axonal transport and degradation. *Neurobiol Aging* 34:2146–2157. https://doi.org/10.1016/j.neurobiolaging.2013.03.015

127. Roman AY, Devred F, Byrne D, La Rocca R, Ninkina NN, Peyrot V, Tsvetkov PO (2019) Zinc induces temperature-dependent reversible self-assembly of tau. *J Mol Biol* 431(4):687–695. doi: https://doi.org/10.1016/j.jmb.2018.12.008

128. Rosseels J, Van den Brande J, Violet M, Jacobs D, Grognet P, Lopez J, Huvent I, Caldara M, Swinnen E, Papegaey A, Caillierez R, Buée-Scherrer V, Engelborghs S, Lippens G, Colin M, Buée L, Galas M-C, Vanmechelen E, Winderickx J (2015) Tau monoclonal antibody generation based on humanized yeast models: impact on tau oligomerization and diagnostics. *J Biol Chem* 290:4059–4074. https://doi.org/10.1074/jbc.M114.627919

129. Sahara N, Maeda S, Murayama M, Suzuki T, Dohmae N, Yen S-H, Takashima A (2007) Assembly of two distinct dimers and higher-order oligomers from full-length tau. *Eur J Neurosci* 25:3020–3029. https://doi.org/10.1111/j.1460-9568.2007.05555.x

130. Sato C, Barthélemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM, Kanaan NM, Yarasheski KE, Baker-Nigh A, Benzinger TLS, Miller TM, Karch CM, Bateman RJ (2018) Tau kinetics in neurons and the human central nervous system. *Neuron* 97:1284–1298.e7. https://doi.org/10.1016/j.neuron.2018.02.015

131. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJW, McFarlane HT, Madsen AØ, Riekel C, Eisenberg D (2007) Atomic structures of amyloid cross-beta spines reveal varied steric zippers. *Nature* 447:453–457. https://doi.org/10.1038/nature05695

132. Sayas CL, Medina M, Cuadros R, Ollá I, García E, Pérez M, Ferrer I, Hernández F, Avila J (2019) Role of tau N-terminal motif in the secretion of human tau by end binding proteins. *PLoS One* 14:e0210864. https://doi.org/10.1371/journal.pone.0210864

133. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser262)

134. Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, Jagust W (2018) Biomarkers for tau pathology. *Mol Cell Neurosci*. https://doi.org/10.1016/j.mcn.2018.12.001

135. Seidler PM, Boyer DR, Rodriguez JA, Sawaya MR, Cascio D, Murray K, Gonen T, Eisenberg DS (2018) Structure-based inhibitors of tau aggregation. *Nat Chem* 10:170–176. https://doi.org/10.1038/nchem.2889

136. Shih HH, Tu C, Cao W, Klein A, Ramsey R, Fennell BJ, Lambert M, Ní Shúilleabháin D, Autin B, Kouranova E, Laxmanan S, Braithwaite S, Wu L, Ait-Zahra M, Milici AJ, Dumin JA, LaVallie ER, Arai M, Corcoran C, Paulsen JE, Gill D, Cunningham O, Bard J, Mosyak L, Finlay WJJ (2012) An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoprotein recognition. *J Biol Chem* 287:44425–44434. https://doi.org/10.1074/jbc.M112.415935

137. Shimada H, Shinotoh H, Sahara N, Hirano S, Furukawa S, Takahata K, Ito H (2015) Diagnostic utility and clinical significance of tau PET imaging with [11C] PBB3 in diverse tauopathies. 9th Hum Amyloid Imaging Conf 2015 Miami, FL, USA

138. Siddiqua A, Luo Y, Meyer V, Swanson MA, Yu X, Wei G, Zheng J, Eaton GR, Ma B, Nussinov R, Eaton SS, Margittai M (2012) Conformational basis for asymmetric seeding barrier in filaments of three- and four-repeat tau. *J Am Chem Soc* 134:10271–10278. https://doi.org/10.1021/ja30498q

139. Skrabana R, Kontsek P, Mederlyova A, Iqbal K, Novak M (2004) Folding of Alzheimer's core PHF subunit revealed by monoclonal antibody 423. *FEBS Lett* 568:178–182. https://doi.org/10.1016/j.feblet.2004.04.098

140. Smith R, Wibom M, Pawlik D, Englund E, Hansson O (2018) Correlation of in vivo [18F]Flortaucipir with postmortem Alzheimer disease tau pathology. *JAMA Neurol*. https://doi.org/10.1001/jamaneurol.2018.3692

141. Sotirooulos I, Galas M-C, Silva JM, Skoulakis E, Wegmann S, Maina MB, Blum D, Sayas CL, Mandelkow E-M, Mandelkow E, Spillantini MG, Sousa N, Avila J, Medina M, Mudher A, Buee L (2017) Atypical, non-standard functions of the microtubule associated tau protein. *Acta Neuropathol Commun* 5:91. https://doi.org/10.1186/s40478-017-0489-6

142. Spillantini MG, Crowther RA, Goedert M (1996) Comparison of the neurofibrillary pathology in Alzheimer's disease and familial presenile dementia with tangles. *Acta Neuropathol (Berl)* 92:42–48

143. Spires-Jones TL, Kopeikina KJ, Koffie RM, de Calignon A, Hyman BT (2011) Are tangles as toxic as they look? *J Mol Neurosci* MN 45:438–444. https://doi.org/10.1007/s12031-011-9566-7

144. Steen H, Mair W, Tang S, Steen JA (2017) Mapping the Tauopathy-specific modification landscape on tau. *Alzheimers Dement* 13:1229. https://doi.org/10.1016/j.jalz.2017.07.426

145. Stefanoska K, Volkerling A, Bertz J, Poljak A, Ke YD, Ittner LM, Ittner A (2018) An N-terminal motif unique to primate tau enables differential protein-protein interactions. *J Biol Chem* 293:3710–3719. https://doi.org/10.1074/jbc.RA18.001784

146. Stephens A, Seibyl J, Mueller A, Barret O, Berndt M, Madonia J, Kroth H, Bullich S, Pfeifer A, Muhs A, Tamagnan G, Marek K, Dinkelborg L (2018) CLINICAL UPDATE: [18F]PI-2620, a next generation tau PET agent evaluated in subjects with Alzheimer's disease and progressive supranuclear palsy. *Alzheimers Dement* 14:P179. https://doi.org/10.1016/j.jalz.2018.06.2287

147. Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TLS, Stops EEJ, Vanderstichele HMJ, Brix B, Darby HD, Vandijck MLJ, Ladenson JH, Morris JC, Holtzman DM, Fagan AM (2015) Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. *JAMA Neurol* 72:1029–1042. https://doi.org/10.1001/jame neurol.2015.1285

148. Taniguchi-Watanabe S, Arai T, Kametani F, Nonaka T, Masuda-Suzukake M, Tarutani A, Murayama S, Saito Y, Arima K, Yoshida M, Akiyama H, Robinson A, Mann DMA, Iwatsubo T, Hasegawa M (2016) Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. *Acta Neuropathol (Berl)* 131:267–280. https://doi.org/10.1007/s00401-015-1503-3

149. Tepper K, Biernat J, Kumar S, Wegmann S, Timm T, Hubschmann S, Redecke L, Mandelkow EM, Muller DJ, Mandelkow E (2014) Oligomer formation of tau protein hyperphosphorylated in cells. *J Biol Chem* 289:34389–34407. https://doi.org/10.1074/jbc.M114.611368

150. Tsvetkov PO, Makarov AA, Malesinski S, Peyrot V, Devred F (2012) New insights into tau-microtubules interaction revealed by isothermal titration calorimetry. *Biochimie* 94:916–919. https://doi.org/10.1016/j.biochi.2011.09.011
151. Tsvetkov PO, Roman AY, Baksheeva VE, Nazipova AA, Shevelyova MP, Vladimirov VI, Buyanova MF, Zinchenko DV, Zamyatnin AA, Devred F, Golovin AV, Permyakov SE, Zernii EY (2018) Functional status of neuronal calcium Sensor-1 is modulated by zinc binding. Front Mol Neurosci 11:459. https://doi.org/10.3389/fnmol.2018.00459

152. Tuttle MD, Comellas G, Nieuwkoop AJ, Covell DJ, Berthold DA, Kloepper KD, Courtney JM, Kim JK, Barclay AM, Kendall A, Wan W, Stubbs G, Schwieters CD, Lee VMY, George JM, Rienstra CM (2016) Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. Nat Struct Mol Biol 23: 409–415. https://doi.org/10.1038/nsmb.3194

153. Vandermeeren M, Borgers M, Van Kolen K, Theunis C, Vasconcelos B, Bottelbergs A, Wintmolders C, Daneels G, Willems R, Dockx K, Delbroek L, Marreiro A, Ver Donck L, Sousa C, Nanjunda R, Lacy E, Van De Casteele T, Van Dam D, De Deyn PP, Kemp JA, Malia TJ, Mercken MH (2018) Anti-tau monoclonal antibodies derived from soluble and filamentous tau show diverse functional properties in vitro and in vivo. J Alzheimers Dis JAD 65: 265–281. https://doi.org/10.3233/JAD-180404

154. Vanhelmont T, Vandebroek T, De Vos A, Terwel D, Lemaire K, Anandhakumar J, Franssens V, Swinnen E, Van Leuven F, Winderickx J (2010) Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast. FEMS Yeast Res 10:992–1005. https://doi.org/10.1111/j.1567-1364.2010.00662.x

155. Vermeiren C, Motte P, Viot D, Mairet-Coello G, Courade J-P, Citron M, Mercier J, Hannestad J, Gillard M (2018) The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord Off J Mov Disord Soc 33:273–281. https://doi.org/10.1002/mds.27271

156. von Bergen M, Barghorn S, Jeganathan S, Mandelkow EM, Mandelkow E (2006) Spectroscopic approaches to the conformation of tau protein in solution and in paired helical filaments. Neurodegener Dis 3:197–206. https://doi.org/10.1159/000095257

157. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E (2000) Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif (306) VQIVYK (311) forming beta structure. Proc Natl Acad Sci U A 97:5129–5134 doi: 97/10/5129

158. Wang JZ, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25:59–68

159. Wasmer C, Lange A, Van Melckebeke H, Siemer AB, Riek R, Meier BH (2008) Amyloid fibrils of the HET-s (218-289) prion form a beta solenoid with a triangular hydrophobic core. Science 319:1523–1526. https://doi.org/10.1126/science.1151839

160. Watt NT, Whitehouse IJ, Hooper NM (2010) The role of zinc in Alzheimer's disease. Int J Alzheimers Dis 2011:971021. https://doi.org/10.4061/2011/971021

161. Wegmann S, Eftekharzadeh B, Tepper K, Zoltowska KM, Bennett RE, Dujardin S, Laskowski PR, MacKenzie D, Kamath T, Commins C, Vanderburg C, Roe AD, Fan Z, Molliex AM, Hernandez-Vega A, Muller D, Hyman AA, Mandelkow E, Taylor JP, Hyman BT (2018) Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J 37. https://doi.org/10.15252/embj.201798049

162. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci U A 72:1858–1862

163. Weismiller HA, Murphy R, Wei G, Ma B, Nussinov R, Margittai M (2018) Structural disorder in four-repeat tau fibrils reveals a new mechanism for barriers to cross-seeding of tau isoforms. J Biol Chem 293(45):17336-17348. https://doi.org/10.1074/jbc.RA118.005316

164. Wiedemann C, Bellstedt P, Görlach M (2013) CAPITO—a web server-based analysis and plotting tool for circular dichroism data. Bioinforma Oxf Engl 29:1750–1757. https://doi.org/10.1093/bioinformatics/btt278

165. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA (1988) Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85:4884–4888

166. Wischik CM, Novak M, Thøgersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, Klug A (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85:4506–4510

167. Witman GB, Cleveland DW, Weingarten MD, Kirschner MW (1976) Tubulin requires tau for growth onto microtubule initiating sites. Proc Natl Acad Sci U S A 73:4070–4074

168. Yin H, Kuret J (2006) C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett 580:211–215. https://doi.org/10.1016/j.febslet.2005.11.077

169. Zhang H, Zhu X, Pascual G, Wadia JS, Keogh E, Hoozemans JJ, Siregar B, Inganås H, Stoop EJM, Goudsmit J, Apetri A, Koudstaal W, Wilson IA (2018) Structural basis for recognition of a unique epitope by a human anti-tau antibody. Structure 26:1626–1634. https://doi.org/10.1016/j.str.2018.08.012

170. Zhang W, Falcon B, Murzin AG, Fan J, Crowther RA, Goedert M, Scheres SH (2019) Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer's and Pick's diseases. eLife 8:e43584. https://doi.org/10.7554/eLife.43584

171. Zhang Z, Song M, Liu X, Kang SS, Kwon I-S, Duong DM, Seyfried NT, Hu WT, Liu Z, Wang J-Z, Cheng L, Sun YE, Yu SP, Levey AI, Ye K (2014) Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat Med 20:1254–1262. https://doi.org/10.1038/nm.3700

172. Zhong Q, Congdon EE, Nagaraja HN, Kuret J (2012) Tau isoform composition influences rate and extent of filament formation. J Biol Chem 287:20711–20719. https://doi.org/10.1074/jbc.M112.364067

173. Zilka N, Kovacech B, Barath P, Kontsekova E, Novák M (2012) The self-perpetuating tau truncation circle. Biochem Soc Trans 40:681–686. https://doi.org/10.1042/BST20120015

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission

• thorough peer review by experienced researchers in your field

• rapid publication on acceptance

• support for research data, including large and complex data types

• gold Open Access which fosters wider collaboration and increased citations

• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

BMC